Lv4
440 积分 2023-11-18 加入
The Treatment of Marginal Zone Lymphoma
5天前
已完结
Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma
1个月前
已完结
Management of relapsed or refractory large B‐cell lymphoma: A British Society for Haematology Guideline
1个月前
已完结
Peripheral T- and natural killer-cell lymphomas: ESMO–EHA Clinical Practice Guideline for diagnosis, treatment and follow-up
3个月前
已完结
How I manage acute respiratory failure in patients with hematological malignancies
4个月前
已完结
The Future of Follicular Lymphoma Management: Strategies on the Horizon
4个月前
已关闭
Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy
5个月前
已完结
Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial
6个月前
已完结
Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma
6个月前
已完结
Primary Large B-cell Lymphomas of Immune-Privileged Sites
7个月前
已完结
皖公网安备34019202002308
